[Doxapram in stable obstructive chronic respiratory insufficiency. A prospective study on 15 cases (author's transl)].
The oral form of Doxapram, a respiratory analeptic drug with central action, was tested prospectively and successively, the subject being his own control, in 15 patients with stable obstructive chronic respiratory insufficiency (OCRI), but not infected and with a high PaCO2. The efficiency of the product was judged notable nine times, medium four times; only twice was its action judged inefficient. Retrospectively, it was not possible to define the group OCRI with high PaCO2, responding or not to the oral form of Doxapram. In these conditions, the utility of prescribing this molecule is subjected to the control of gasometric efficiency before and after absorption. The frequent efficiency of the product leads to the consideration of a regular use in some obstructive chronic respiratory insufficiency.
D000368:Aged; D002245:Carbon Dioxide / Q000097:blood; D004315:Doxapram / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000097:blood / Q000188:drug therapy*; D008297:Male; D010100:Oxygen / Q000097:blood; D011446:Prospective Studies; D012131:Respiratory Insufficiency / Q000097:blood / Q000188:drug therapy*
D002245:Carbon Dioxide; D004315:Doxapram; D010100:Oxygen
Le doxapram dans l'insuffisance respiratoire chronique obstructive stable. Etude prospective portant sur 15 cas.